MINOCA

in review 5 min read Updated 2026-10-19
MINOCA

Myocardial injury with non-obstructive coronary arteries (5th UDMI 2026): suspected MI, no stenosis ≥50% — a working diagnosis; CMR confirms MI in only ~¼, the rest are mostly myocarditis, Takotsubo or cardiomyopathy. Workup: re-review angiogram (SCAD, branch occlusion), echo, CMR within 2 weeks ± OCT, then provocation testing for spasm/CMD. Treat the mechanism; everyone gets cardiac rehab.

MINOCA

Myocardial injury with non-obstructive coronary arteries (5th UDMI) — working diagnosis when suspected MI meets an angiogram with no stenosis ≥50%. After CMR, MI is the final diagnosis in only 22–27%; most have myocarditis, Takotsubo, cardiomyopathy or a non-cardiac cause (PE). Confirmed MI → reclassify as primary, secondary or procedure-related → myocardial injury and MI classification.

  • 6–15% of MI; younger, ~2× more often female (1 in 8 MIs in women <55), more often NSTEMI than STEMI.
  • Same angiogram, normal troponin → ANOCA/INOCA.
  • Mimics: takotsubo syndrome, myocarditis → myopericarditis.
  • SCAD with >50% obstruction is not MINOCA, but missed SCAD is often labelled MINOCA until OCT/IVUS or re-review → spontaneous coronary artery dissection.
  • Prognosis not benign: death/MI ~2× that of matched patients without ASCVD; mimics have outcomes like obstructive MI → establish the cause during the admission.

coronary causes

causemechanismclue
plaque disruption (rupture, erosion, calcified nodule) — most commonthrombus on non-obstructive plaque ± distal embolisationmild plaque in RWMA territory
vasospasm (epicardial or microvascular) → [[angina with non-obstructive coronary arteriesANOCA]]smooth-muscle hyperreactivity; triggers: smoking, cocaine, 5-FU, allergen (Kounis), phaeochromocytoma
coronary microvascular dysfunction (CMD)impaired NO-mediated vasodilation → ↓ flow reservestress perfusion defect on CMR/PET
coronary embolism (<3%)AF/LA thrombus, prosthetic valve, [[infective endocarditisendocarditis]], paradoxical (PFO/ASD), thrombophilia
SCADintramural haematoma compresses lumenyoung woman, FMD, peripartum, stressor

HARP (2021) (women, OCT + CMR): OCT culprit in 46% (plaque disruption 43%); CMR non-ischaemic cause in 20%; combined abnormality in 85%. Cause unknown in 8–25% despite full workup.


diagnostic cascade

flowchart TD
  A["suspected MI, no stenosis ≥50%"] --> B["alternative explanation?<br/>Takotsubo, contusion, tachyarrhythmia,<br/>PE, cardiotoxin, severe sepsis"]
  B -- yes --> X["treat cause"]
  B -- no --> C["TTE (all)<br/>+ re-review angiogram:<br/>missed SCAD, branch occlusion, obstructive CAD"]
  C --> D["CMR in hospital (≤2 weeks)<br/>and/or return to cath lab for OCT"]
  D --> E["ischaemic LGE + oedema, one territory → MI → OCT for culprit"]
  D --> F["multifocal ischaemic LGE ± LV thrombus → embolism"]
  D --> G["stress perfusion defect → CMD"]
  D --> H["oedema, no LGE, non-coronary distribution → Takotsubo"]
  D --> I["subepicardial/mid-wall LGE + oedema → myocarditis"]
  E --> J["OCT negative → ACh provocation ± coronary physiology"]

CMR-first or OCT-first both acceptable by local access; transfer if neither available.

testtierwhat it adds
hs-troponin (sex-specific), CBC, CRPfirst-lineconfirms injury; anaemia, inflammation, infection; supply–demand triggers
TTE (± contrast)first-line, allRWMA territory, Takotsubo pattern, cardiomyopathy, valve/pericardium, embolic source
CMRfirst-linewithin 2 weeks (Takotsubo oedema, mild myocarditis and small infarcts fade); still diagnostic in ≥50% later
OCT / IVUSfirst-linerupture/erosion/nodule, mural thrombus, SCAD, intimal bumping (spasm); OCT > IVUS for erosion
ACh / ergonovine provocationsupplementaryepicardial spasm (COVADIS: pain + ischaemic ECG + >90% constriction) or microvascular spasm; safe within 48 h; criteria → [[angina with non-obstructive coronary arteries
coronary physiologysupplementaryCFR, microcirculatory resistance → CMD; thresholds → [[angina with non-obstructive coronary arteries
CTAsupplementaryplaque, myocardial bridge; alternative if invasive angiography declined
PET flowsupplementary↓ myocardial flow reserve; limited Canadian access
TOE/bubble, thrombophiliasupplementarysuspected embolism → haematology

CMR patterns

LGE / oedemadiagnosis
subendocardial or transmural LGE + oedema, one coronary territoryinfarct
ischaemic LGE in several territories ± LV thrombusembolism
oedema without LGE, coronary distributionvasospasm (severe spasm can give subendocardial LGE)
oedema without LGE, apical/mid/basal non-coronary distributiontakotsubo syndrome
subepicardial/patchy mid-wall LGE + oedema ± effusionmyocarditis → [[acute pericarditis
normalbest prognosis (10-y MACE ~3.5% vs ~47% with infarct)

treatment by mechanism

Expert opinion — no RCT of pharmacotherapy specifically in MINOCA.

causetherapystrength (CCS 2024)
plaque disruptionas obstructive MI: ASA + P2Y12 inhibitor (clopidogrel or ticagrelor), high-intensity statin (LDL ↓ >50% and <1.8 mmol/L), ACEi (class I) or ARB (IIa) if LVEF <40%, hypertension, diabetes or stable CKD, beta-blocker → post-MI careper MI guidelines
SCADASA + beta-blocker; conservative over PCI unless unstable; no routine statin → spontaneous coronary artery dissectionshould be strongly considered
vasospasmCCB ± nitrate; remove triggers; beta-blocker with caution → [[angina with non-obstructive coronary arteriesANOCA]]
CMDantianginals (beta-blocker, CCB, nitrate, ranolazine); ACEi + statin if otherwise indicated — ANOCA data favour beta-blocker + ACEi + statin first, CCB less certain → [[angina with non-obstructive coronary arteriesANOCA]]
embolismanticoagulate if AF, intracardiac or prosthetic valve thrombus; PFO/ASD closure if paradoxical; thrombophilia → haematologyper source guidelines
unknown causestatin (all), ACEi/ARB; beta-blocker only if another indication; DAPT by most likely mechanismmay be considered
allcardiac rehab (RCT n=524: ↓ death, MACE); risk factors; psychosocial support; allergen avoidance if Kounis; complex → women’s heart centre (BC, ON, QC, NS)—
  • Statins: observational MACE HR 0.34–0.77; reaching LDL targets ↓ MACE 32% (SWEDEHEART). ACEi/ARB: meta-analysis (n=10 546) MACE HR 0.65, no mortality signal. DAPT and beta-blockers: null.
  • SCAD without stent → DAPT benefit uncertain; menorrhagia → ASA alone.

Prepared 2026-10-19. Not yet verified — check every number against the sources.

Key references

Suggest a correction MINOCA